Last reviewed · How we verify
ranibizumab, dexamethasone and verteporfin
ranibizumab, dexamethasone and verteporfin is a Small molecule drug developed by Bay Area Retina Associates. It is currently in Phase 2 development.
At a glance
| Generic name | ranibizumab, dexamethasone and verteporfin |
|---|---|
| Sponsor | Bay Area Retina Associates |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself (PHASE2)
- Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL) (PHASE2)
- Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ranibizumab, dexamethasone and verteporfin CI brief — competitive landscape report
- ranibizumab, dexamethasone and verteporfin updates RSS · CI watch RSS
- Bay Area Retina Associates portfolio CI
Frequently asked questions about ranibizumab, dexamethasone and verteporfin
What is ranibizumab, dexamethasone and verteporfin?
ranibizumab, dexamethasone and verteporfin is a Small molecule drug developed by Bay Area Retina Associates.
Who makes ranibizumab, dexamethasone and verteporfin?
ranibizumab, dexamethasone and verteporfin is developed by Bay Area Retina Associates (see full Bay Area Retina Associates pipeline at /company/bay-area-retina-associates).
What development phase is ranibizumab, dexamethasone and verteporfin in?
ranibizumab, dexamethasone and verteporfin is in Phase 2.